Gianluca Pirozzi
Director/Board Member bij TREX WIND-DOWN, INC.
Vermogen: 1 $ op 31-03-2024
Profiel
Gianluca Pirozzi is an Independent Director at Timber Pharmaceuticals, Inc. since 2020 and a Senior VP, Head-Development, Regulatory & Safety at Alexion Pharmaceuticals, Inc. since 2019.
Previously, he worked as a Director at Imbria Pharmaceuticals, Inc. from 2018 to 2020 and as the Head-Rare Diseases at Genzyme Corp.
from 2018 to 2019.
He also held the position of Head-Gene Therapy at Genzyme Therapeutics Ltd.
Additionally, he served as the Head-Development for Rare Diseases & Gene Therapy at Sanofi SA from 2014 to 2019.
Dr. Pirozzi holds a doctorate degree from Sapienza University of Rome and Università Campus Bio-Medico di Roma.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
TREX WIND DOWN INC
0.10% | 07-09-2023 | 3 366 ( 0.10% ) | 1 $ | 31-03-2024 |
Actieve functies van Gianluca Pirozzi
| Bedrijven | Functie | Begin |
|---|---|---|
| TREX WIND-DOWN, INC. | Director/Board Member | 01-05-2020 |
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01-10-2019 |
Eerdere bekende functies van Gianluca Pirozzi
| Bedrijven | Functie | Einde |
|---|---|---|
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director/Board Member | 01-05-2020 |
| Sanofi SA | Corporate Officer/Principal | 01-09-2019 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van Gianluca Pirozzi
| Sapienza University of Rome | Doctorate Degree |
| Università Campus Bio-Medico di Roma | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| TREX WIND-DOWN, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
| Sanofi SA | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
